Back to top

Image: Bigstock

Intercontinental Exchange (ICE) Q1 Earnings Top Estimates

Read MoreHide Full Article

Have you been eager to see how Intercontinental Exchange, Inc. (ICE - Free Report) , one of the largest global stock and derivative exchange operators, performed in Q1 in comparison with the market expectations? Let’s quickly scan through the key facts from this Atlanta, GA-based company’s earnings release this morning.

Earnings Beat Estimates

Intercontinental Exchange reported adjusted earnings per share of 90 cents, beating the Zacks Consensus Estimate of 88 cents. Bottom-line improved 21.6% year over year.

How Was the Estimate Revision Trend?

You should note that the earnings estimate for Intercontinental Exchange depicted neutral stance prior to the earnings release. The Zacks Consensus Estimate remained unchanged at 88 cents over the last 7 days.

Also, Intercontinental Exchange has a decent earnings surprise history.

Overall, the company surpassed the Zacks Consensus Estimate by an average beat of 1.3% in the trailing four quarters.

Revenues Beat Estimates

Intercontinental Exchange’s revenues of $1.23 billion increased 5.1% year over year. Revenues marginally beat the Zacks Consensus Estimate of $1.22 billion.

Key Takeaways

Total operating expenses decreased 1.5% year over year to $575 million.

Operating income improved 11.7% to $650 million.    

Adjusted operating expenses is estimated between $500 million and $510 million for the second quarter of 2018 and between $2 billion and $2.04 billion for 2018.

What Zacks Rank Says

Intercontinental Exchange carries Zacks Rank#3 (Hold). However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. Now it all depends on what sense the just-released report makes to the analysts.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Check back later for our full write up on this Intercontinental Exchange earnings report later!

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Intercontinental Exchange Inc. (ICE) - free report >>

Published in